• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

脂蛋白纳米药物传输系统研究进展

王若宁, 刘聪燕, 周建平, 陈键, 王伟

王若宁, 刘聪燕, 周建平, 陈键, 王伟. 脂蛋白纳米药物传输系统研究进展[J]. 中国药科大学学报, 2014, 45(1): 10-16. DOI: 10.11665/j.issn.1000-5048.20140102
引用本文: 王若宁, 刘聪燕, 周建平, 陈键, 王伟. 脂蛋白纳米药物传输系统研究进展[J]. 中国药科大学学报, 2014, 45(1): 10-16. DOI: 10.11665/j.issn.1000-5048.20140102
shu
WANG Ruoning, LIU Congyan, ZHOU Jianping, CHEN Jian, WANG Wei. Advances in the research of lipoprotein-based nano scale drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(1): 10-16. DOI: 10.11665/j.issn.1000-5048.20140102
Citation: WANG Ruoning, LIU Congyan, ZHOU Jianping, CHEN Jian, WANG Wei. Advances in the research of lipoprotein-based nano scale drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(1): 10-16. DOI: 10.11665/j.issn.1000-5048.20140102
shu

脂蛋白纳米药物传输系统研究进展

  • 1.

    中国药科大学天然药物活性组分与药效国家重点实验室

  • 2.

    中国药科大学药剂学教研室

  • 3.

    复旦大学药学院智能化递药教育部重点实验室

基金项目: 国家自然科学基金资助项目(No.81102398,81273469)；江苏省自然科学基金资助项目(No.BK2011624)；复旦大学药学院和智能化递药教育部重点实验室(复旦大学)开放课题资助项目(No.SDD2012-03)；中央高校基本科研业务费专项基金资助项目(No.JKVD2013011)

Advances in the research of lipoprotein-based nano scale drug delivery systems

摘要

    摘要
  • 摘要: 〓脂蛋白作为一种内源性纳米颗粒，具有生物相容性好、可彻底生物降解、无免疫原性、不被体内网状内皮系统识别而快速清除等优点，是一种极具前景的靶向药物载体。本文综述了近年来基于脂蛋白(乳糜微粒、极低密度脂蛋白、低密度脂蛋白和高密度脂蛋白)的纳米药物传输系统的最新研究进展。
    Abstract: Lipoproteins which are endogenous, biocompatible, completely biodegradable, and non-immunogenic, and can escape recognition and elimination by the reticuloendothelial system(RES)may well be studied as drug carriers. This article summarizes the advances in lipoprotein(chylomicrons, very low-density lipoprotein, low-density lipoprotein and high-density lipoprotein)-based nano scale drug delivery systems(LNDDS)in recent years.
    • HTML全文
    • 参考文献(42)
  • [1] Ng KK,Lovell JF,Zheng G.Lipoprotein-inspired nanoparticles for cancer theranostics[J].Acc Chem Res,2011,44(10):1 105-1 113.
    [2] Thaxton CS,Daniel WL,Giljohann DA,et al.Templated spherical high density lipoprotein nanoparticles[J].J Am Chem Soc,2009,131(4):1 384-1 385.
    [3] Gershkovich P,Hoffman A.Uptake of lipophilic drugs by plasma derived isolated chylomicrons:linear correlation with intestinal lymphatic bioavailability[J].Eur J Pharm Sci,2005,26(5):394-404.
    [4] Dierling AM,Cui Z.Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapy[J].Int J Pharm,2005,303(1):143-152.
    [5] Kader A,Pater A.Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells[J].J Control Release,2002,80(1):29-44.
    [6] Pieper-Furst U,Lammert F.Low-density lipoprotein receptors in liver:old acquaintances and a newcomer[J].Biochim Biophys Acta,2013,1 831(7):1 191-1 198.
    [7] Nelson T,Quattrone A,Alkon D.Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier: US,802727[P].2004-06-17[2008-07-03].
    [8] Kopecka J,Campia I,Olivero P,et al.A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells[J].J Control Release,2011,149(2):196-205.
    [9] Nikanjam M,Gibbs AR,Hunt CA,et al.Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme[J].J Control Release,2007,124(3):163-171.
    [10] Jin H,Lovell JF,Chen J,et al.Mechanistic insights into LDL nanoparticle-mediated siRNA delivery[J].Bioconjugate Chem,2011,23(1):33-41.
    [11] Marotta DE,Cao W,Wileyto EP,et al.Evaluation of bacteriochlorophyll-reconstituted low-density lipoprotein nanoparticles for photodynamic therapy efficacy in vivo[J].Nanomedicine(Lond),2011,6(3):475-487.
    [12] Hill ML,Corbin IR,Levitin RB,et al.In vitro assessment of poly-iodinated triglyceride reconstituted low-density lipoprotein:initial steps toward CT molecular imaging[J].Acad Radiol,2010,17(11):1 359-1 365.
    [13] Crich SG,Lanzardo S,Alberti D,et al.Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles[J].Neoplasia,2007,9(12):1 046-1 056.
    [14] Frias JC,Lipinski MJ,Lipinski SE,et al.Modified lipoproteins as contrast agents for imaging of atherosclerosis[J].Contrast Media Mol Imaging,2007,2(1):16-23.
    [15] Allijn IE, Leong W, Tang J, et al. Gold nanocrystal labeling allows low density lipoprotein imaging from the subcellular to macroscopic level[J].ACS Nano,2013,7(11):9 761-9 770.
    [16] Huntosova V,Buzova D,Petrovajova D,et al.Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells[J].Int J Pharm,2012,436(1/2):463-471.
    [17] Chen J,Corbin IR,Li H,et al.Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo[J].J Am Chem Soc,2007,129(18):5 798-5 799.
    [18] Rensen PC,de Vrueh RL,Kuiper J,et al.Recombinant lipoproteins:lipoprotein-like lipid particles for drug targeting[J].Adv Drug Deliv Rev,2001,47(2):251-276.
    [19] Liu X,Suo R,Xiong SL,et al.HDL drug carriers for targeted therapy[J].Clin Chim Acta,2013,415:94-100.
    [20] Davis ME,Chen ZG,Shin DM.Nanoparticle therapeutics:an emerging treatment modality for cancer[J].Nat Rev Drug Discov,2008,7(9):771-782.
    [21] Lacko AG,Nair M,Paranjape S,et al.High density lipoprotein complexes as delivery vehicles for anticancer drugs[J] Anticancer Res,2002,22(4):2 045.
    [22] McConathy WJ,Nair MP,Paranjape S,et al.Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel[J].Anti-cancer Drug,2008,19(2):183-188.
    [23] Lou B, Liao XL, Wu MP, et al. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells[J].World J Gastroenterol,2005,11(7):954-959.
    [24] Ghosh M,Singh AT,Xu W,et al.Curcumin nanodisks:formulation and characterization[J].Nanomedicine,2011,7(2):162-167.
    [25] Singh AT,Evens AM,Anderson RJ,et al.All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma[J] Brit J Haematol,2010,150(2):158-169.
    [26] Zhang X,Chen B.Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin[J].Cancer Lett,2010,298(1):26-33.
    [27] Liu CY,Wang W,Zhou JP,et al.Preparation and evaluation of gambogic acid loaded reconstituted high density lipoprotein nanoparticles[J].J China Pharm Univ(中国药科大学学报),2013,44(4):311-315.
    [28] Zhang WL,Gu X,Bai H,et al.Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug[J].Int J Pharm,2010,391(1/2):313-321.
    [29] Feng M,Cai Q,Shi X,et al.Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells[J].J Drug Target,2008,16(6):502-508.
    [30] Oda MN,Hargreaves PL,Beckstead JA,et al.Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B[J].J Lipid Res,2006,47(2):260-267.
    [31] Dykxhoorn DM.RNA interference as an anticancer therapy:a patent perspective[J].Expert Opin Ther Pat,2009,19(4):475-491.
    [32] Wolfrum C,Shi S,Jayaprakash KN,et al.Mechanisms and optimization of in vivo delivery of lipophilic siRNAs[J].Nat Biotechnol,2007,25(10):1 149-1 157.
    [33] Ding Y,Wang W,Feng M,et al.A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy[J].Biomaterials,2012,33(34):8 893-8 905.
    [34] Rui M,Tang H,Li Y,et al.Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA[J].Pharm Res,2013,30(5):1 203-1 214.
    [35] Zhang Z,Cao W,Jin H,et al.Biomimetic nanocarrier for direct cytosolic drug delivery[J].Angew Chem Int Ed Engl,2009,48(48):9 171-9 175.
    [36] McMahon KM,Mutharasan RK,Tripathy S,et al.Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery[J].Nano Lett,2011,11(3):1 208-1 214.
    [37] Chen W, Vucic E, Leupold E, et al. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis[J].Contrast Media Mol I,2008,3(6):233-242.
    [38] Cormode DP,Skajaa T,van Schooneveld MM,et al.Nanocrystal core high-density lipoproteins:a multimodality contrast agent platform[J].Nano Lett,2008,8(11):3 715-3 723.
    [39] Cao W,Ng KK,Corbin I,et al.Synthesis and evaluation of a stable bacteriochlorophyll-analog and its incorporation into high-density lipoprotein nanoparticles for tumor imaging[J].Bioconjugate Chem,2009,20(11):2 023-2 031.
    [40] Zhang Z,Chen J,Ding L,et al.HDL‐mimicking peptide-lipid nanoparticles with improved tumor targeting[J].Small,2010,6(3):430-437.
    [41] Chen W,Jarzyna PA,van Tilborg GA,et al.RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe[J].FASEB J,2010,24(6):1 689-1 699.
    [42] Corbin IR,Chen J,Cao W,et al.Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers[J].J Biomed Nanotechnol,2007,3(4):367-376.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1606
  • HTML全文浏览量:  3
  • PDF下载量:  2707
  • 被引次数: 0
出版历程
  • 刊出日期:  2014-02-24

目录

摘要
HTML全文
    参考文献(42)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：336161

    x 关闭 永久关闭